- Home
- LILAK vs PTGX Comparison
LILAK vs PTGX Comparison
Compare LILAK & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILAK
- PTGX
- Stock Information
- Founded
- LILAK 2017
- PTGX 2006
- Country
- LILAK Bermuda
- PTGX United States
- Employees
- LILAK N/A
- PTGX N/A
- Industry
- LILAK Cable & Other Pay Television Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- LILAK Telecommunications
- PTGX Health Care
- Exchange
- LILAK Nasdaq
- PTGX Nasdaq
- Market Cap
- LILAK 1.1B
- PTGX 3.7B
- IPO Year
- LILAK N/A
- PTGX 2016
- Fundamental
- Price
- LILAK $7.90
- PTGX $58.59
- Analyst Decision
- LILAK Hold
- PTGX Strong Buy
- Analyst Count
- LILAK 2
- PTGX 9
- Target Price
- LILAK $7.85
- PTGX $70.44
- AVG Volume (30 Days)
- LILAK 1.2M
- PTGX 906.1K
- Earning Date
- LILAK 11-05-2025
- PTGX 11-06-2025
- Dividend Yield
- LILAK N/A
- PTGX N/A
- EPS Growth
- LILAK N/A
- PTGX N/A
- EPS
- LILAK N/A
- PTGX 0.80
- Revenue
- LILAK $4,409,700,000.00
- PTGX $209,180,000.00
- Revenue This Year
- LILAK $1.21
- PTGX N/A
- Revenue Next Year
- LILAK $2.90
- PTGX $185.11
- P/E Ratio
- LILAK N/A
- PTGX $72.57
- Revenue Growth
- LILAK N/A
- PTGX N/A
- 52 Week Low
- LILAK $4.23
- PTGX $33.31
- 52 Week High
- LILAK $10.67
- PTGX $61.89
- Technical
- Relative Strength Index (RSI)
- LILAK 53.89
- PTGX 53.66
- Support Level
- LILAK $7.57
- PTGX $54.50
- Resistance Level
- LILAK $8.33
- PTGX $60.40
- Average True Range (ATR)
- LILAK 0.23
- PTGX 2.70
- MACD
- LILAK -0.09
- PTGX -0.14
- Stochastic Oscillator
- LILAK 43.79
- PTGX 55.35
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.